Published in Gene Therapy Weekly, July 8th, 2004
Under the agreement, Raven will receive an upfront payment and potential future milestone and royalty payments. Further terms of the agreement were not disclosed.
"We have been impressed with the discoveries that Raven has made using their proprietary technologies," stated W. Michael Gallatin, PhD, ICOS vice president and scientific director. "This collaboration expands ICOS'...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly